Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741384 | 0.93 | KDM1A (0.40) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL741386 | 0.92 | KDM1A (0.46) | CYP19A1KDM1ACYP11B2CYP11B1 | |
| SCHEMBL3396999 | 0.91 | CYP19A1 (0.37) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL762940 | 0.90 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL3368777 | 0.89 | KDM1A (0.37) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL742444 | 0.85 | KDM1A (0.39) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL3370381 | 0.84 | CYP19A1 (0.34) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL3368780 | 0.83 | KDM1A (0.40) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL762885 | 0.83 | — | — | |
| SCHEMBL3366305 | 0.81 | CYP17A1 (0.33) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010540-B1 | SPIRO-IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007116098-A1 | SPIRO-IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | CYP19A1 104/4885KDM1A 3697/4885CYP11B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.